Prostacyclin pathway vasodilators in patients with chronic thromboembolic pulmonary hypertension (CTEPH): A systemic review and meta-analysis of randomized controlled trials.

Mean pulmonary arterial pressure The mPAP was reported in four studies, 6 , 16 , 18 , 19 which showed a trend improvement in the prostacyclin pathway vasodilator treatment compared to controls.

also in 53,322 other papers

PVR, mRAP, cardiac index, and WHO functional class were significantly improved in CTEPH patients treated with the prostacyclin pathway vasodilators compared to the controls, additionally, there was an observed trend towards improvement in mPAP, 6MWD, and NT‐proBNP.

also in 504 other papers